Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies

ABSTRACT: Triple-negative breast cancer (TNBC) is the most heterogeneous and aggressive subtype of breast carcinoma, defined by the absence of clinical biomarkers and the lack of targeted therapies. Despite numerous clinical trials, patient stratification remains suboptimal, limiting the identification of effective treatment strategies. In this study, we aimed to identify biomarkers exclusively expressed in the basal mammary epithelial compartment to refine TNBC subclassification. Through computational analysis of single-cell RNA sequencing data, we defined a set of basal identity genes, which were subsequently validated by immunohistochemistry in two independent TNBC cohorts. This approach enabled the identification of a novel TNBC subgroup, termed true basal TNBC (tB-TNBC), associated with poorer prognosis and distinct molecular features. To uncover therapeutic vulnerabilities in this subgroup, we conducted a high-throughput screen of 3,200 FDA-approved compounds in breast cancer cell lines classified by basal marker expression. This analysis identified dasatinib as a promising candidate with selective activity against tB-TNBC models. Furthermore, TAGLN emerged as a strong predictive biomarker of dasatinib response, with functional studies confirming its role in modulating drug sensitivity. Altogether, these findings support the clinical utility of basal markers for TNBC stratification and highlight a targeted treatment opportunity for tB-TNBC patients.

ORGANISM(S): Homo sapiens

PROVIDER: GSE300385 | GEO | 2026/02/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptomic Profiling of Immune Cell-Enriched Regions in Triple-Negative Breast Cancer Using Targeted RNA Sequencing

Project description:Triple-negative breast cancer (TNBC), characterized by the lack of hormone receptors and HER2 expression, remains a challenging subtype due to the absence of effective targeted therapies. Tumor budding (TB), a histopathological feature reflecting invasive potential, has recently emerged as a valuable prognostic marker across various cancers, including TNBC. Identifying transcriptomic alterations associated with high TB is critical for understanding mechanisms of tumor progression and immune evasion. In this study, we employed TempO-Seq, a high-throughput targeted RNA sequencing technology, to profile gene expression in immune cell-enriched regions of breast cancer tissues. Our objective was to uncover immune-related biomarkers and gene signatures specific to high TB cases, with the ultimate goal of informing prognostic stratification and potential therapeutic targets in aggressive breast cancer subtypes.

2025-08-21 | GSE305953 | GEO

Targeted RNA-sequencing of formalin-fixed paraffin-embedded breast cancer tissue samples

Project description:The presence of over-expressed receptors in triple-negative breast cancer (TNBC) leads to the absence of targeted therapy. Tumor budding (TB) has emerged as a recent prognostic indicator. It is essential to pinpoint genes unique to high TB cases to prevent tumor advancement and spread. In this study, we utilized TempO-Seq to profile transcriptomic data from breast cancer samples to identify biomarkers for high TB cases.

2024-09-13 | GSE262825 | GEO

Identification of Src Family Kinases as potential therapeutic targets for chemotherapy-resistant triple negative breast cancer

Project description:Neoadjuvant chemotherapy (NAC) remains the cornerstone of treatment for triple negative breast cancer (TNBC) with the goal of complete eradication of disease. However, for patients with residual disease after NAC, recurrence and mortality rates are high and identification of novel therapeutic targets are urgently needed. Here we quantified tyrosine phosphorylation (pTyr) mediated signaling networks in chemotherapy sensitive (CS) and resistant (CR) TNBC patient derived xenografts (PDX) to gain novel therapeutic insights. We identified Src Family Kinases (SFKs) as potential therapeutic targets in CR TNBC PDXs. Treatment with dasatinib, an FDA approved SFK inhibitor, led to inhibition of tumor growth in vivo. Further analysis of post-treatment PDXs revealed multiple mechanisms of actions of the drug confirming the multi-target inhibition of dasatinib. Direct analysis of pTyr in tumor specimens from TNBC patients suggest a low prevalence of SFK driven tumors in the clinic which may explain why clinical trials evaluating dasatinib failed in unselected breast cancer patients. Taken together, these results underscore the importance of pTyr characterization of tumors in identifying new targets as well as stratifying patients based on their activated signaling networks for therapeutic options. Our data also suggest that treatment with an SFK inhibitor may benefit a subset of TNBC patients with CR disease.

2022-09-20 | GSE204825 | GEO

Bulk RNA-seq of MDA-MB-231 cells under dasatinib treatment

Project description:Triple-negative breast cancer (TNBC) is characterized by high metastatic potential and poor prognosis, underscoring the urgent need for effective therapeutic strategies. Dasatinib emerged as a promising anti-metastatic agent in TNBC.To elucidate the molecular mechanisms by which dasatinib inhibits breast cancer progression, we conducted bulk RNA sequencing (RNA-seq) on MDA-MB-231 cells treated for 6, 12, 24, and 48 hours.

2025-09-27 | GSE308797 | GEO

Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping

Project description:Triple-negative breast cancer (TNBC) is considered the most aggressive type of breast cancer with limited options for therapy. TNBC is a heterogeneous disease and tumours has been classified into TNBC subtypes using gene expression profiling to distinguish basal-like1 (BL1), basal-like2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal/stem-like (MSL), luminal androgen receptor (LAR) and one non-classifiable group (called unstable, UNS). The aim of this study was to verify the clinical relevance of molecular subtyping of TNBCs by expression analysis to improve the individual indication of systemic therapy.

2021-07-31 | GSE167213 | GEO

Prognostic signature of epithelial-mesenchymal transition in breast cancer

Project description:Epithelial-mesenchymal transition (EMT), a switch of polarized epithelial cells to a migratory, fibroblastoid phenotype, is considered a key process driving tumor cell invasiveness and metastasis. Using breast cancer cell lines as a model system, we sought to discover gene-expression signatures of EMT with clinical and mechanistic relevance. A supervised comparison of epithelial and mesenchymal breast cancer lines defined a 200-gene EMT signature that was prognostic across multiple breast cancer cohorts. Immunostaining of LYN, a top-ranked EMT signature gene and Src-family tyrosine kinase, was associated with significantly shorter overall survival (P=0.02), and correlated with the basal-like (“triple-negative”) phenotype. In mesenchymal breast cancer lines, RNAi-mediated knockdown of LYN inhibited cell migration and invasion, but not proliferation. Dasatinib, a dual-specificity tyrosine kinase inhibitor, also blocked invasion (but not proliferation) at nanomolar concentrations that inhibit LYN kinase activity, suggesting that LYN is a likely target and invasion a relevant endpoint for dasatinib therapy. Our findings define a prognostically-relevant EMT signature in breast cancer, and identify LYN as a mediator of invasion and possible new therapeutic target (and theranostic marker for dasatinib response), with particular relevance to clinically-aggressive basal-like breast cancer. Cell Line: cell line(epithelial-like/fibroblast-like/normal breast fibroblasts) Keywords: Logical Set

2010-04-11 | GSE13915 | GEO

FER drives tumor progression cues of invasive breast cancer cells through kinase-dependent control of proliferation and endosomal recycling

Project description:Triple-Negative Breast Cancer (TNBC) is a poorly targetable cancer subtype that exhibits a high metastatic potential. To develop new intervention strategies, it is crucial to understand the mechanisms governing migratory and invasive features of TNBC cells. Previously it was shown that high expression of the non-receptor tyrosine kinase FER is an independent prognostic factor that correlates with poor survival in high grade and basal breast cancer. Here, we show that FER controls proliferation and invasion of TNBC cells through the direct substrates MAPK1 and Dynactin 2 (DCTN2; Dynamitin). Our data demonstrate that FER regulates tumor cell proliferation through phosphorylation of MAPK1 on tyrosine 187, and recycling endosome function and subsequent invasion of breast cancer cells through tyrosine 6 residue (Y6) of DCTN2. We show that DCTN2-Y6 is essential for Dynein complex formation and the development of tubular recycling domains at the early endosome. By controlling this crucial step in endosomal recycling, FER drives and sustains adhesion and invasion of (triple negative) breast cancer cells. Our data provide clinical ramification by demonstrating that high grade and basal breast cancers expressing elevated FER levels are more susceptible to taxane-based chemotherapy interventions. In conclusion, our study links FER to kinase-dependent control of intracellular vesicular transport and tumor progression in breast cancer. Importantly, our results indicate that FER represents a predictive and functional biomarker in high grade basal breast cancers.

2022-04-15 | PXD021307 | Pride

Prognostic signature of epithelial-mesenchymal transition in breast cancer

2010-04-11 | E-GEOD-13915 | biostudies-arrayexpress

Comprehensive proteomic characterization reveals subclass-specific molecular aberrations within triple-negative breast cancer

Project description:Triple-negative breast cancer (TNBC) is regarded as the most aggressive subtype of breast cancer lacking targeted therapies. This is attributed to its high heterogeneity that complicates elucidation of its molecular aberrations. Here, we report identification of specific proteome expression profiles pertaining to two TNBC subclasses, basal A and basal B, through in-depth proteomics analysis of breast cancer cells. We observed that kinases and proteases displayed unique expression patterns within the subclasses, similar to whole proteome clusters. Systematic analyses of protein-protein interaction and co-regulation networks of these kinases and proteases unraveled dysregulated pathways and plausible targets for each TNBC subclass. Among these, we identified kinases AXL, PEAK1 and TGFBR2, and proteases FAP, UCHL1 and MMP2/14, as specific targets for basal B subclass, which represents the more aggressive TNBC cell lines. Our study thus highlights intricate mechanisms and distinct targets within TNBC, and emphasizes that these have to be exploited in a subclass-specific manner rather than a one-for-all TNBC therapy.

2020-03-03 | PXD017025 | Pride

Impact of EMT-driven plasticity on phenotypic diversity dynamics under chemotherapy [spontaneous]

Project description:Triple negative breast cancer (TNBC) is the most lethal breast cancer subgroup, as lack of targeted therapies and drug resistance reduce survival rates. Cellular plasticity enables cells to adapt non-genetically and overcome therapeutic pressure, thereby embodying a critical clinical hurdle. The epithelial-mesenchymal transition (EMT) is an example of phenotypic reprogramming linked to plasticity, drug resistance and metastasis. However, its exact impact on population diversity under therapeutic pressure is unknown. Here, we used single cell transcriptomics to investigate phenotypic diversity dynamics upon drug treatment in two human in vitro models of TNBC plasticity.

2024-12-04 | GSE263729 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data